PROUS SCIENCE INTEGRITY. Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective
|
|
- Kathleen Houston
- 6 years ago
- Views:
Transcription
1 PROUS SCIENCE INTEGRITY Leukemia Therapy: Bcr-Abl Kinase Inhibitors: Selective vs Nonselective
2 SUMMARY In this use case, active compounds for Leukemia will be found and filtered by mechanisms of action and organization. Comparing two launched products for this condition, Gleevec and Tasigna, a structure search will be run to find structure-activity relationships for specific Bcr-Abl kinase inhibitors. From specific Abl kinase inhibitors list, related targets associated to these drugs will be examined and the targetscape for Acute Myeloiod Leukemia will be explored
3 LEUKEMIA Leukemia is a malignant disease of the bone marrow and blood that is characterized by the uncontrolled accumulation of white blood cells About 4,400 people in the U.S. will die of Chronic lymphocytic leukemia during 2009, according to the American Cancer Society. Among patients with Acute lymphocytic leukemia in the U.S., approximately 1,400 are predicted to die during the same year; two-thirds of these would be adults. Approximately 470 people with Chronic myelogenous leukemia and 9,000 with Acute myelogenous leukemia are expected to die as a cause of their disease this year in the U.S. The treatment of leukemia is complex and is based on a range of factors including characteristics of the disease itself (type of leukemia, extent of disease, whether or not the disease has been treated previously) and patient characteristics (age, symptoms and general health). Chemotherapy is the primary treatment for acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL), although the specific drugs used to treat each form differ. In some cases radiotherapy or stem cell transplantation may be used in combination with chemotherapy.
4 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Go to the Drugs & Biologics Knowledge Area from the pull down menu at the left part of the home page of Integrity
5 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Click the down arrow to open the pull-down of search fields and select Development Status -> Condition in this example.
6 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Next open the Browse Index of search terms for the search field chosen, run a preliminary lookup search to locate a term in the index, and then click the term on the right to copy it to the Search Form.
7 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Add other relevant criteria to the Search Form in this example, select Development Status -> Under Active Development = Y Click Start or hit return to launch the search.
8 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH From the list of active development programs for leukemia, retrieve the corresponding products by selecting the Product List from the Options pulldown menu
9 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Use the Filter by Statistics charts to further limit the search. From the Product List obtained, filter by Organization
10 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Check the companies of interest and click View Subset(s) In this example, select the Novartis and Novartis Oncology checkboxes
11 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH Select the Full Record option from the Options pull-down menu
12 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH The product record for Imatinib mesylate shows that it acts on multiple targets, including Abl Kinase and Bcr- Abl Kinase
13 DRUGS & BIOLOGICS KNOWLEDGE AREA: GUIDED SEARCH The product record for Nilotinib Hydrochloride Monohydrate shows that it acts selectively on Bcr- Abl Kinase. To further investigate selectivity of similar compounds a substructure search can be run.
14 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH To set up a structure search, select a Knowledge Area Drugs & Biologics in this example and click the Structure Search button to go to the Structure Search Form.
15 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Draw or paste a structure in the structure search window.
16 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Combine a substructure search with a text search by opening the search field menu and selecting a field - in this example, Therapeutic Group. Then open the Then open the corresponding Browse Index to select a term.
17 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Use the Lookup box in the Browse Index to locate terms in the hierarchical Therapeutic Group index. Then click a term -- Oncolytic Drugs in this example -- to copy it to the Search Form.
18 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Click Start or press Return to launch a search for products with this Therapeutic Group classification and that share a similar substructure.
19 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH Compounds can be classified quickly and easily by using Filter by Statistics. In this example, select to filter by Molecular Mechanisms.
20 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH The chart shows that many of the compounds have more than one mechanism of action. Using the checkbox function, select Bcr-Abl Kinase Inhibitors and click View Subset(s) to view the subset of compounds with this mechanism.
21 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH From the original list of product records retrieved that are Oncolytic Drugs and that have a similar structure, these are the compounds that are Bcr-Abl kinase inhibitors. Select the Product List with Structures from the pull-down menu
22 DRUGS & BIOLOGICS KNOWLEDGE AREA: STRUCTURE SEARCH From this list, structure-activity relationships can be examined. Access to Experimental Pharmacology, Pharmacokinetics/ Metabolism and other data can be obtained through the All Related Information via Quick Search
23 INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS Select the Targets & Pathways enabled bar
24 INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS From the Targets & Pathways list obtained, select the Targetscapes option
25 INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS Click on the Acute Myeloid Leukemia Targescape
26 INFORMATION RETRIEVAL VIA TARGETS & PATHWAYS to view the molecular landscape for this condition.
27 SUPPORT/HELP For questions about Integrity s contents or features, send a message via the Help Request / Suggestion Form in Integrity or contact
Tasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationAllergy Basics. This handout describes the process for adding and removing allergies from a patient s chart.
Allergy Basics This handout describes the process for adding and removing allergies from a patient s chart. Accessing Allergy Information Page 1 Recording No Known Medication Allergies Page 2 Recording
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationBlood Cancer: Chronic Myelogenous Leukaemia
Published on: 30 May 2017 Blood Cancer: Chronic Myelogenous Leukaemia What Is Cancer? The body is made up of cells that grow and die in a controlled way. Sometimes, cells keep dividing and growing without
More informationModule 3: Pathway and Drug Development
Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7
More informationCHRONIC MYELOGENOUS LEUKEMIA. By Ting Huai Shi Pd. 6
CHRONIC MYELOGENOUS LEUKEMIA By Ting Huai Shi Pd. 6 PHYSIOLOGY Chronic myelogenous leukemia (CML) is one of four forms of leukemia. It is caused by a spontaneous somatic mutations, and therefore, non-hereditary.
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationStudying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)
A service of the U.S. National Institutes of Health Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY) This study is currently recruiting participants.
More informationA Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
A service of the U.S. National Institutes of Health Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting Trial record 1 of 1 for: CABL001X2101 Previous Study Return to List
More informationBLOOD AND LYMPH CANCERS
BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber
More informationPatient information brochure
Clinical Development and Medical Affairs Patient information brochure 1. European Medicines Agency. Nilotinib Summary of Product Characteristics. March 2013. Available from: www.ema.europa.eu/ema/index.
More informationCIBMTR Center Number: CIBMTR Recipient ID: Today s Date: Date of HSCT for which this form is being completed:
Chronic Myelogenous Leukemia (CML) Post-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic,
More informationAdd_A_Class_with_Class_Search_Revised Thursday, March 18, 2010
Slide 1 Text Captions: PAWS Tutorial "Add a Class using Class Search" Created for: Version 9.0 Date: March, 2010 Slide 2 Text Captions: Objective In this tutorial you will learn how to add a class to your
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationSelf Assessment 8.3 to 8.4.x
Self Assessment 8.3 to 8.4.x User Guide November 30, 2009 Contents What Self Assessments does Managing self assessments Creating self assessments Adding questions to your self assessment Grading and answers
More informationAdd_A_Class_with_Class_Number_Revised Thursday, March 18, 2010
Slide 1 Text Captions: PAWS Tutorial "Add a Class using Class Number" Created for: Version 9.0 Date: March, 2010 Slide 2 Text Captions: Objective In this tutorial you will learn how to add a class to your
More informationPBSI-EHR Off the Charts!
PBSI-EHR Off the Charts! Enhancement Release 3.2.1 TABLE OF CONTENTS Description of enhancement change Page Encounter 2 Patient Chart 3 Meds/Allergies/Problems 4 Faxing 4 ICD 10 Posting Overview 5 Master
More informationClinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Tasigna) Reference Number: CP.CPA.162 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationExercise Pro Getting Started Guide
Exercise Pro Getting Started Guide Table Of Contents Installation... 1 Overview... 1 Tutorial... 1 The Exercise Pro 6 Interface... 1 Searching and Selecting Exercises... 2 Printing the Exercise Program...
More informationRefilling a Prescription with No Refills Remaining
................................................................................................... Refilling a Prescription with No Refills Remaining Pharmacy Technology Solutions May, 2013 Refilling
More informationHEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA
LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationTitrations in Cytobank
The Premier Platform for Single Cell Analysis (1) Titrations in Cytobank To analyze data from a titration in Cytobank, the first step is to upload your own FCS files or clone an experiment you already
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationStudy Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)
We are updating the design of this site. Learn more. Try the new test version at https://clinicaltrials.gov/beta/ Show less Find Studies About Studies Submit Studies Resources About Site Trial record 1
More informationHow a CML Patient and Doctor Work Together
How a CML Patient and Doctor Work Together Recorded on: November 5, 2012 Jessica Altman, M.D. Assistant Professor, Department of Medicine, Hematology Oncology Division Feinberg School of Medicine, Northwestern
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationChronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE
Chronic Myelogenous Leukemia (Hematology) By DEISSEROTH READ ONLINE If searched for the ebook by DEISSEROTH Chronic Myelogenous Leukemia (Hematology) in pdf format, in that case you come on to correct
More informationChapter 1: Managing workbooks
Chapter 1: Managing workbooks Module A: Managing worksheets You use the Insert tab on the ribbon to insert new worksheets. True or False? Which of the following are options for moving or copying a worksheet?
More informationBCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib
BCCA Protocol Summary for Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using PONAtinib Protocol Code Tumour Group Contact Physician ULKCMLP Leukemia Dr. Donna Forrest ELIGIBILITY:
More informationGleevec. Gleevec (imatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationHematologic Malignancies 2013 Retrospective Study at Truman Medical Center
Hematologic Malignancies 2013 Retrospective Study at Truman Medical Center Kristen Strasser, MD & Abdulraheem Qasem, MD Introduction: Hematologic Malignancies includes malignant diseases of the bone marrow
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationPedCath IMPACT User s Guide
PedCath IMPACT User s Guide Contents Overview... 3 IMPACT Overview... 3 PedCath IMPACT Registry Module... 3 More on Work Flow... 4 Case Complete Checkoff... 4 PedCath Cath Report/IMPACT Shared Data...
More informationPhiladelphia Positive (Ph+) Chronic Myeloid Leukaemia
Advocacy toolkit In this toolkit, we take a look into the treatments for Philadelphia-positive Chronic Myeloid Leukaemia (CML) that have led to treatment free remission (TFR) being one of the biggest topics
More informationThe Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon
The Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon Imatinib revolutionized the treatment of chronic myelogenous leukemia (CML), improving the prognosis to such an extent that the
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationDistribution of Leukemia in Chennai Population:- An Epidemiological Study
Research Article Distribution of Leukemia in Chennai Population:- An Epidemiological Study Devika Warrier E*, MP Brundha Department of General Pathology, Saveetha University, 162, P.H Road, Chennai, Tamil
More informationLeukemias and Lymphomas Come From Normal Blood Cells
Leukemias and Lymphomas Come From Normal Blood Cells by Steve Anderson, Ph.D. Steve Anderson has a Ph.D. in Immunology with 25 years experience in biomedical research. His scientific expertise includes
More informationscreening procedures Disease resistant to full-dose imatinib ( 600 mg/day) or intolerant to any dose of imatinib
Table S1. Study inclusion and exclusion criteria Inclusion criteria Aged 18 years Signed and dated informed consent form prior to protocol-specific screening procedures Cytogenetic- or PCR-based diagnosis
More informationCancer and Tyrosine Kinase Inhibition
Cancer and Tyrosine Kinase Inhibition 1 Motivation (1) In first world countries cancer is the second most common cause of death after cardiovascular diseases. For most tumors, treatment is limited to surgery,
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationFacts On Leukemia By American Cancer Society
Facts On Leukemia By American Cancer Society If you are searching for a book Facts on Leukemia by American Cancer Society in pdf format, then you've come to the loyal site. We presented the complete edition
More informationNIH BIOSKETCH CLINIC
NIH BIOSKETCH CLINIC University of Massachusetts Medical School Research Funding Services Lamar Soutter Library UMMS Available under CC-BY-NC 3.0 You will need: era Commons login and password SUMMIT login
More informationFacts LEUKEMIA LYMPHOMA MYELOMA
Facts 2009-2010 Table of Contents Figures 1 Executive Summary 3 About Blood Cancer Therapy Drug and Radiation Therapy Stem Cell Transplantation Quality of Life Survivorship 7 Leukemia Living with Leukemia
More informationLeukemia. There are different types of leukemia and several treatment options for each type.
Leukemia Introduction Leukemia is the name of a group of cancers of the blood cells. Hundreds of thousands of people worldwide are diagnosed with leukemia each year. There are different types of leukemia
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationJuly 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American
More informationA medicine to block the amount of acid produced in the stomach (H2 blocker): about 10 hours before about 2 hours after
TRACKING JOURNAL YOUR TRACKING JOURNAL Throughout your treatment with TASIGNA (nilotinib), your doctor will prescribe regular tests to see if your treatment is working. It s important to keep up with your
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationAge Disparity in the Dissemination of Imatinib Mesylate (Gleevec) for Treating Chronic Myeloid Leukemia
Age Disparity in the Dissemination of Imatinib Mesylate (Gleevec) for Treating Chronic Myeloid Leukemia Chuck Wiggins, Ph.D. Director and Principal Investigator New Mexico Tumor Registry North American
More informationTRANSPARENCY COMMITTEE OPINION. 14 February 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 February 2007 GLIVEC 100 mg, capsule B/120 capsules (CIP: 358 493-5) GLIVEC 100 mg, capsule B/180 capsules (CIP:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at
More informationPart 2: Cancer Therapies, Present and Future. Adrianna San Roman Leah Liu Clare Malone
Part 2: Cancer Therapies, Present and Future Adrianna San Roman Leah Liu Clare Malone Objec?ves Most cancer therapies aback general features common to all cancers New cancer therapies aback specific features
More informationChronic Pain Management Workflow Getting Started: Wrenching In Assessments into Favorites (do once!)
Chronic Pain Management Workflow Getting Started: Wrenching In Assessments into Favorites (do once!) 1. Click More Activities to star flowsheets into your chunky button screen. 3. Use the search function
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: ASP 2215-cl-0101 Previous Study Return to List Next Study Dose Escalation Study Inv e stigating the Safe ty, Tole rability,
More informationProScript User Guide. Pharmacy Access Medicines Manager
User Guide Pharmacy Access Medicines Manager Version 3.0.0 Release Date 01/03/2014 Last Reviewed 11/04/2014 Author Rx Systems Service Desk (T): 01923 474 600 Service Desk (E): servicedesk@rxsystems.co.uk
More informationTARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
More informationInstructor Guide to EHR Go
Instructor Guide to EHR Go Introduction... 1 Quick Facts... 1 Creating your Account... 1 Logging in to EHR Go... 5 Adding Faculty Users to EHR Go... 6 Adding Student Users to EHR Go... 8 Library... 9 Patients
More informationImatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
ORIGINAL ARTICLE Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia Bahoush Gr, 1 Alebouyeh M, 2 Vossough P 1 1 Pediatric Hematology-Oncology Department, Ali-Asghar Children's Hospital,
More informationBE THE MATCH. The Role of HLA in Finding a Match for Bone Marrow or Peripheral Blood Stem Cell Transplantation
BE THE MATCH The Role of HLA in Finding a Match for Bone Marrow or Peripheral Blood Stem Cell Transplantation Leukemia Leukemia is a type of cancer of the blood or bone marrow. It is characterized by an
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sprycel) Reference Number: CP.PHAR.72 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1037-6 Program Prior Authorization/Notification Medication Gleevec (imatinib mesylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationForm 2011 R4.0: Acute Lymphoblastic Leukemia (ALL) Pre-HCT Data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Date of HCT for which this form is being completed: - - HCT type: (check all that apply) Autologous Allogeneic,
More informationMAGIC BULLETS A CASE ON ENZYME INHIBITION
National Center for Case Study Teaching in Science MAGIC BULLETS A CASE ON ENZYME INHIBITION by Sarah A. Wojiski School of Arts and Sciences MCPHS University, Boston, MA Just a routine checkup? Oliver
More informationPrecision Medicine Knowledgebase (PMKB)
Precision Medicine Knowledgebase (PMKB) https://pmkb.weill.cornell.edu/ https://academic.oup.com/jamia/article/24/ 3/513/2418181/The-cancer-precisionmedicine-knowledge-base-for Click on this to expand/collapse
More informationAn Initiative to Equip Health-System Pharmacists to Select and Manage Drug Therapy for the Disease
An Initiative to Equip Health-System Pharmacists to Select and Manage Drug Therapy for the Disease What Health-System Pharmacists Should Know About CML Chronic myelogenous leukemia (CML, also known as
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationTHE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA. Ava Greco
THE USE OF WT1-QPCR TO MEASURE AND DETECT MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA Ava Greco REVIEW OF LITERATURE What is Leukemia? Abnormal growth of cells in the blood stream Progresses rapidly
More informationhmhco.com National GO Math! K 6 USER GUIDE Personal Math Trainer Powered by Knewton
hmhco.com National GO Math! K 6 USER GUIDE Personal Math Trainer Powered by Knewton Version.0 August 015 Contents I. OVERVIEW AND MODES OF THE PMT...3 II. LOCATING THE PMT TO MAKE ASSIGNMENTS...5 III.
More informationCharge Posting. General Principles. Insurance Payments for Services
Charge Posting General Principles Insurance Payments for Services ICD-9 Codes are the diagnostic codes used by insurance companies, including Medicare, for determining whether a service is going to paid
More informationHere are the various choices. All of them are found in the Analyze menu in SPSS, under the sub-menu for Descriptive Statistics :
Descriptive Statistics in SPSS When first looking at a dataset, it is wise to use descriptive statistics to get some idea of what your data look like. Here is a simple dataset, showing three different
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder
More informationCreating YouTube Captioning
Creating YouTube Captioning Created June, 2017 Upload your video to YouTube Access Video Manager Go to Creator Studio by clicking the option from your account icon located in the topright corner of the
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase Warren E, Ward S, Gordois A, Scuffham P Record Status This is a critical abstract of an
More informationLeukemia (The Biology of Cancer)
Leukemia (The Biology of Cancer) Donna M. Bozzone Click here if your download doesn"t start automatically Leukemia (The Biology of Cancer) Donna M. Bozzone Leukemia (The Biology of Cancer) Donna M. Bozzone
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Anemia(s), 412 426 categories in morphologic approach to, macrocytic, 412 414 microcytic, 412 414 normocytic, 412 413 categorizing, 412
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Nilotinib SYNONYM(S): nilotinib hydrochloride monohydrate 1 COMMON TRADE NAME(S): TASIGNA CLASSIFICATION: miscellaneous Special pediatric considerations are noted when applicable, otherwise
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationThe Clinical Information Data Entry Screen is the main screen in the DQCMS application.
DATA ENTRY Clinical Information The Clinical Information Data Entry Screen is the main screen in the DQCMS application. To enter data, a patient must first be selected from the Patient pull-down list.
More informationTechnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta426
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta426 NICE 2017. All rights reserved. Subject to
More informationDementia Direct Enhanced Service
Vision 3 Dementia Direct Enhanced Service England Outcomes Manager Copyright INPS Ltd 2015 The Bread Factory, 1A Broughton Street, Battersea, London, SW8 3QJ T: +44 (0) 207 501700 F:+44 (0) 207 5017100
More informationTechnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta425
More informationDOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF ACUTE LEUKEMIAS NEW DIRECTIONS FOR CLINICAL RESEARCH REPRINT PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of acute leukemias new directions for clinical research reprint
More informationVocabulary: cell division, centriole, centromere, chromatid, chromatin, chromosome, cytokinesis, DNA, interphase, mitosis
Cell Division Answer Key Vocabulary: cell division, centriole, centromere, chromatid, chromatin, chromosome, cytokinesis, DNA, interphase, mitosis Prior Knowledge Questions (Do these BEFORE using the Gizmo.)
More informationMaking a Room Reservation with Service Requests in Virtual EMS
Making a Room Reservation with Service Requests in Virtual EMS Step 1: Pull up Virtual EMS by navigating from any browser to schedule.ucdenver.edu/virtualems. Step 2: Navigate to My Account>>Log In>>Enter
More informationMoffitt s Program In Malignant Hematology: A decade of discovery: from cytotoxic treatments to targeted therapies
SPRING 2014, VOL. 15, ISSUE 1 Moffitt s Program In Malignant Hematology: A decade of discovery: from cytotoxic treatments to targeted therapies Moffitt Cancer Center s program in Malignant Hematology was
More information